Agenus (NASDAQ:AGEN - Get Free Report)'s stock had its "neutral" rating reaffirmed by stock analysts at HC Wainwright in a report released on Wednesday,Benzinga reports.
Agenus Price Performance
NASDAQ:AGEN opened at $2.05 on Wednesday. The firm has a market capitalization of $48.09 million, a price-to-earnings ratio of -0.18 and a beta of 1.23. The business has a fifty day moving average price of $3.24 and a 200-day moving average price of $3.85. Agenus has a one year low of $1.93 and a one year high of $19.69.
Agenus (NASDAQ:AGEN - Get Free Report) last posted its earnings results on Tuesday, March 11th. The biotechnology company reported ($2.04) EPS for the quarter, topping analysts' consensus estimates of ($2.36) by $0.32. The firm had revenue of $26.84 million during the quarter, compared to analysts' expectations of $30.09 million. On average, equities research analysts expect that Agenus will post -12.55 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Agenus
A number of large investors have recently added to or reduced their stakes in the company. Deutsche Bank AG raised its stake in shares of Agenus by 538.4% in the fourth quarter. Deutsche Bank AG now owns 61,144 shares of the biotechnology company's stock worth $168,000 after purchasing an additional 51,566 shares during the last quarter. Corton Capital Inc. purchased a new position in shares of Agenus in the fourth quarter valued at approximately $36,000. Bank of America Corp DE lifted its stake in shares of Agenus by 34.0% in the fourth quarter. Bank of America Corp DE now owns 107,123 shares of the biotechnology company's stock worth $294,000 after buying an additional 27,157 shares in the last quarter. Jane Street Group LLC boosted its holdings in shares of Agenus by 97.6% during the 4th quarter. Jane Street Group LLC now owns 105,705 shares of the biotechnology company's stock worth $290,000 after purchasing an additional 52,215 shares during the last quarter. Finally, B. Riley Financial Inc. purchased a new stake in Agenus in the 4th quarter valued at $2,074,000. 61.46% of the stock is currently owned by institutional investors.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
